EGFR and prostate cancer: For diabetes, the main pathways included neuroactive ligand-receptor interaction, pathways in cancer, cAMP signaling pathway, calcium signaling pathway, lipid and atherosclerosis, inflammatory mediator regulation of TRP channels, prostate cancer, insulin resistance, AGE-RAGE signaling pathway in diabetic complications, and EGFR tyrosine kinase inhibitor resistance (Figure 4F).